U.S. markets closed

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.49-0.07 (-0.18%)
At close: 4:00PM EDT

Phathom Pharmaceuticals, Inc.

100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
http://www.phathompharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Ms. Terrie J. CurranPres, CEO & Director560.72kN/A1969
Dr. Azmi Nabulsi M.D., M.P.H.Chief Operating Officer608.73kN/A1960
Mr. Aditya Kohli Ph.D.Chief Bus. Officer319.65kN/A1989
Mr. Todd P. BranningChief Financial OfficerN/AN/A1971
Mr. Joseph Hand J.D.Chief Admin. OfficerN/AN/AN/A
Mr. Lawrence Miller Esq., J.D.Gen. Counsel & Sec.N/AN/AN/A
Mr. Tom HarrisHead of Regulatory AffairsN/AN/AN/A
Dr. Eckhard Leifke M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Mr. Martin J. GilliganChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Corporate Governance

Phathom Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.